These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24917706)

  • 1. Significance of uracil/tegafur for preventing intravesical recurrence of non-muscle invasive urothelial carcinoma of the bladder.
    Harada K; Miyake H; Terakawa T; Fujisawa M
    Curr Urol; 2012 May; 6(1):27-32. PubMed ID: 24917706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma.
    Nagai N; Mukai K; Hirata E; Jin HH; Komatsu M; Yunokawa M
    Med Oncol; 2008; 25(2):214-21. PubMed ID: 17968681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.
    Liu B; Miyake H; Nishikawa M; Fujisawa M
    Urol Oncol; 2015 Mar; 33(3):110.e11-8. PubMed ID: 25262382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer.
    Emi Y; Sumiyoshi Y; Oki E; Kakeji Y; Fukui Y; Maehara Y
    Fukuoka Igaku Zasshi; 2007 Dec; 98(12):418-24. PubMed ID: 18260367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The intravesical recurrence after 3-day consecutive intravesical instillation of pirarubicine hydrochloride (THP) following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer].
    Tochigi T; Sakurada Y; Aoki H; Kawamura S; Itou S; Satou I; Tateno H
    Nihon Hinyokika Gakkai Zasshi; 2012 Jul; 103(4):610-6. PubMed ID: 23120995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prophylactic effect of UFT in combination with intravesical chemotherapy on the recurrence of superficial bladder tumor].
    Yoshida O; Kakehi Y; Nishio Y; Tomoyoshi T; Konami T; Usui T; Igawa M; Takenaka I; Fujita K
    Hinyokika Kiyo; 1992 Dec; 38(12):1437-43. PubMed ID: 1288238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer--intravesical thio-TEPA versus oral UFT.
    Hirao Y; Okajima E; Ozono S; Samma S; Sasaki K; Hiramatsu T; Babaya K; Watanabe S; Maruyama Y
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S26-30. PubMed ID: 1394812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparative clinical trial of UFT treatment and intravesical adriamycin instillation to prevent recurrence of superficial bladder cancer].
    Masuda F; Mori Y; Torii S; Kawashima Y; Kobari T; Hosobe T
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):505-8. PubMed ID: 1558400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.
    Ishizuka M; Kubota K; Nemoto T; Shimoda M; Kato M; Iso Y; Tago K
    Asian J Surg; 2016 Jul; 39(3):149-54. PubMed ID: 26123137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A comparative clinical trial of UFT medication and intravesical BCG in the recurrence of superficial bladder cancer. Study Group of UFT and BCG adjuvant therapy for bladder cancer].
    Oda H; Seki N; Nabeshima S; Oda T; Nishio S; Yokoyama M; Iwata H; Takeuchi M; Matsumoto A; Terado T
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2051-5. PubMed ID: 2221929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial.
    Hasegawa K; Takayama T; Ijichi M; Matsuyama Y; Imamura H; Sano K; Sugawara Y; Kokudo N; Makuuchi M
    Hepatology; 2006 Oct; 44(4):891-5. PubMed ID: 17006925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-angiogenic activities of UFT and its metabolites, GHB and GBL, in the dorsal air sac (DAS) model in mice].
    Basaki Y; Yonekura K; Chikahisa L; Okabe S; Hashimoto A; Miyadera K; Aoyagi K; Yamada Y
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):93-8. PubMed ID: 10660738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UFT in bladder cancer.
    Kubota Y; Noguchi S; Hosaka M
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):112-5. PubMed ID: 10442377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group].
    Uchida K; Takeshima H; Kikuchi K; Shimazui T; Miyanaga N; Kawai K; Akaza H; Tsuchiya A; Noguchi R; Hattori K; Manabe F; Matsuki K; Suzuki R; Ishikawa S; Kondo F; Kobayashi T; Koiso K
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1179-87. PubMed ID: 9679581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic oral UFT therapy for superficial bladder cancer.
    Kubota Y; Hosaka M; Fukushima S; Kondo I
    Cancer; 1993 Mar; 71(5):1842-5. PubMed ID: 8448746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGF-related pathway.
    Basaki Y; Aoyagi K; Chikahisa L; Miyadera K; Hashimoto A; Yonekura K; Okabe S; Shibata J; Wierzba K; Yamada Y
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):68-71. PubMed ID: 11098498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
    Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
    Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
    Basaki Y; Chikahisa L; Aoyagi K; Miyadera K; Yonekura K; Hashimoto A; Okabe S; Wierzba K; Yamada Y
    Angiogenesis; 2001; 4(3):163-73. PubMed ID: 11911014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
    Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
    Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.